Roth Capital keeps a Buy rating on Biofrontera (BFRI) after the company divested the U.S. license for its impetigo drug Xepi to Pelthos Therapeutics (PTHS), for up to $10M. Roth views the proceeds as “essentially found money,” given the drug’s lack of U.S. sales and promotion. The money should fund Biofrontera to profitability, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI: